Global Bovine Respiratory Disease Treatment Market: Trends, Size, Growth, Opportunity and Forecast 2022-2028

 

The most common disease is a bovine respiratory disease (BRD), which affects the lower respiratory tract of cattle, causing bronchopneumonia and can lead to death. It is a multifactorial syndrome caused primarily by the interaction of a viral infection with a bacterial agent, which is exacerbated by stress. BRD is caused by a variety of agents, including bacterial agents like Pasteurella multocida, Haemophilus somnus, and Mannheim hemolytic, as well as viral agents like infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), and parainfluenza type-3 virus (PI-3).

The rising population and rising beef consumption will be major factors driving market growth over the forecast period. Beef consumption is increasing globally due to the rising population and disposable income. Global beef demand is driving the expansion of the bovine respiratory disease treatment market. Due to calf mortality, increased labor costs, and treatment costs, Bovine Respiratory Disease Treatment Market has a negative impact on both the dairy and beef industries. Furthermore, BRD has a negative impact on the reproductive performance, growth, and life span of cattle. As a result, there is a high demand for BRD treatment in the market. Furthermore, to meet the rising demand for beef, most countries are increasing cattle meat production.

BRD is a multifactorial disorder caused by the interaction of several codependent factors, including stress, viral infection, bacterial infection, and environmental factors. The diagnosis of this disease is difficult because there are numerous possible causes of BRD. Bovine Respiratory Disease Treatment Market patients frequently exhibit depression, weight loss, cough, mucopurulent or purulent nasal discharge, fever, increased respiratory rate, and abnormal pulmonary sounds on auscultation. However, presumptive diagnosis after the physical examination is difficult due to clinical sign similarities and bacterial variation. As a result, the difficulties associated with Bovine Respiratory Disease Treatment Market diagnosis are expected to limit the market growth.

Increasing the development of novel treatment methods for bovine respiratory disease in order to boost the market growth.

Zoetis Inc., Bayer AG, Merck & Co., Inc., Virbac Group, Boehringer Ingelheim GmbH, Elanco, Vetoquinol, and Bimeda Animal Health are key players in the bovine respiratory disease treatment market. Bayer introduced Immunostimulant Zelnate in 2015, which effectively reduces bovine respiratory disease (BRD)-related mortality and lung lesions in cattle. The United States Department of Agriculture has approved Senate as the first cytosine-phosphate-guanine (CpG) motif-based immunostimulant.